Scribe's Epigenetic CRISPR Takes Aim at Heart Disease, Not Your DNA

ALAMEDA, CA – April 30, 2026 – In the rapidly evolving world of genetic medicine, Scribe Therapeutics is positioning itself to take a significant leap forward. The biotechnology firm, co-founded by Nobel laureate Jennifer Doudna, is set to unveil pivotal data on its next-generation CRISPR platforms and its lead drug candidate at two prestigious scientific conferences in May. The presentations are expected to highlight a novel approach to treating high cholesterol—one that silences a problematic gene without making permanent, and potentially risky, cuts to a patient's DNA.

Next month, Scribe will present at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting and the European Atherosclerosis Society (EAS) Congress. The focus will be on STX-1150, a therapy designed to lower “bad” LDL cholesterol, and the sophisticated engineered technologies that power it. This move signals a potential paradigm shift, moving advanced gene therapies from the realm of rare diseases toward tackling some of the most prevalent and costly chronic conditions facing global health.

A New Tool for a Common Enemy

The primary target for Scribe's lead program is PCSK9, a well-known protein that plays a critical role in regulating cholesterol levels. For years, pharmaceutical companies have successfully targeted this pathway with antibody drugs like Repatha and Praluent, and more recently with RNA-interference (siRNA) therapies like Leqvio. These treatments have proven effective but require repeated injections for life.

Scribe's STX-1150 aims to offer a more durable solution with a distinct safety advantage. Instead of using traditional CRISPR-Cas9 to cut the PCSK9 gene—an irreversible action—STX-1150 employs the company’s proprietary Epigenetic Long-Term X-Repressor (ELXR) technology. This system acts more like a dimmer switch than a pair of scissors. It places temporary chemical marks on the gene's regulatory region, effectively silencing its expression and dramatically reducing PCSK9 protein levels. The underlying DNA sequence remains untouched.

Preclinical data has been highly encouraging. In non-human primates, a single intravenous dose of STX-1150 resulted in a sustained reduction of LDL cholesterol by over 50% for nearly 18 months, with the effect still ongoing. These results, which Scribe's CEO Benjamin Oakes is slated to present at the EAS Congress, suggest the potential for a “one-and-done” or infrequent dosing regimen that could transform long-term cardiovascular risk management. The company anticipates launching a Phase 1 human trial for STX-1150 in mid-2026.

'CRISPR by Design': Engineering a Better Editor

Underpinning this therapeutic innovation is Scribe's foundational philosophy of “CRISPR by Design.” Rather than using off-the-shelf CRISPR components, the company has built its platforms from the ground up, starting with a different bacterial enzyme called CasX. Naturally smaller than the more famous Cas9, CasX is more easily packaged into the lipid nanoparticle and viral vectors used to deliver genetic medicines into the body.

But Scribe didn't stop there. Through a meticulous molecular engineering process, its scientists have created a suite of proprietary X-Editor (XE) molecules that are significantly more potent and specific than their natural counterparts. To accelerate this process, Scribe developed DeepXE, an AI-enabled platform that can predict the effectiveness of its engineered editors, dramatically speeding up the discovery of optimal therapeutic candidates.

This holistic engineering approach aims to solve the key challenges that have faced first-generation gene editing: off-target effects, delivery difficulties, and inconsistent potency. The advancements will be detailed at ASGCT by key Scribe scientists, including co-founder Brett Staahl and senior directors Sarah Denny and Emeric Charles, who will discuss the engineering of both the editing and epigenetic repressor systems.

Big Pharma's Billion-Dollar Bet on Scribe's Vision

The potential of Scribe's highly engineered platform has not gone unnoticed. The company has secured major strategic collaborations with pharmaceutical giants, providing a powerful external validation of its technology and a significant infusion of capital to fuel its ambitious pipeline.

A partnership with Sanofi, initially focused on developing next-generation cancer cell therapies, was expanded in 2023 to include in vivo treatments for sickle cell disease. This collaboration, worth a potential $1.2 billion in milestones, leverages Scribe’s technology to edit genes directly inside the body, aiming to create a simpler, more accessible cure for the debilitating blood disorder.

Similarly, a collaboration with Prevail Therapeutics, a subsidiary of Eli Lilly, is aimed at tackling neurological and neuromuscular diseases. This deal brought Scribe $75 million upfront, including an equity investment, with over $1.5 billion in potential future payments. The partnership has already achieved multiple success milestones, signaling tangible progress in applying Scribe's CRISPR X-Editing technologies to notoriously difficult-to-treat diseases.

These alliances not only provide financial runway but also grant Scribe access to the development and commercialization expertise of global industry leaders, accelerating the path from lab to clinic for its novel genetic medicines.

From Rare Disorders to Everyday Health

By targeting hypercholesterolemia—a condition affecting hundreds of millions worldwide—Scribe is making a strategic pivot from the initial focus of many gene therapy companies on rare, monogenic diseases. Success in this area would demonstrate that CRISPR-based technologies can be scaled and safely deployed to address major public health crises.

The company’s mission explicitly includes democratizing access to the protective effects of beneficial human genetics. The development of a long-lasting, potentially titratable, and epigenetically “safer” therapy for high cholesterol is a direct step toward that goal. As Scribe prepares to present its latest breakthroughs, the scientific and medical communities will be watching closely to see if this new chapter in the CRISPR story can deliver on its promise to reshape the treatment of common diseases and improve health for millions.